Global Dementia Drugs

Dementia Drugs Comprehensive Study by Type (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitors), Application (Hospital, Clinics, Others), Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimer's Disease, Vascular Dementia, Others), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026

Dementia Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Dementia Drugs Market?

Dementia is an overall term for loss of memory, language, critical thinking, and other reasoning capacities that are adequately serious to interfere with everyday life. Alzheimer's is the most widely recognized reason for dementia. Treatment of dementia relies upon its cause. On account of most progressive dementias, including Alzheimer's sickness, there is no fix and no therapy that eases back or stops its movement. In any case, there are drug medicines that may briefly improve manifestations. Similar meds used to treat Alzheimer's are among the medications once in a while endorsed to assist with indications of different sorts of dementias. Non-drug treatments can likewise ease a few side effects of dementia.

The market study is being classified by Type (MAO Inhibitors, Cholinesterase Inhibitors and Glutamate Inhibitors), by Application (Hospital, Clinics and Others) and major geographies with country level break-up.

Eisai, Inc (Japan), Janssen Pharmaceuticals, Inc (United States), Biogen Pharmaceuticals(United States), Forest Laboratories, Inc(United States), Eli Lilly and Company(United States), Novartis AG (Switzerland), Sanofi S.A (France), AstraZeneca GmbH, F. Hoffmann-La Roche(Switzerland), Merck & Co., Inc(United States) and Pfizer Inc(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Valeant Pharmaceutical International(United States) and Teva Pharmaceuticals Industries(United States).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Dementia Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Dementia Drugs market by Type, Application and Region.

On the basis of geography, the market of Dementia Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The growing geriatric population

Market Trend
  • Favorable supportive legislation by the government

Restraints
  • The adverse effect of the Dementia Drugs


Challenges
  • Lack of skilled professional


In February 2020 Dementia Drugs has prepared to support the manufacturing of Alzheimer's launch. The unconventional path Biogen’s Alzheimer’s prospect, the US Food, and Drug Administration (FDA) will approve the drug. However, with Biogen confident it has data to show the antibody works, despite it failing a Phase III futility analysis, the big biotech is laying the groundwork for an anticipated launch.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Dementia Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
By Application
  • Hospital
  • Clinics
  • Others
By Indication
  • Lewy Body Dementia
  • Parkinsons Disease Dementia
  • Alzheimer's Disease
  • Vascular Dementia
  • Others

By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Lack of skilled professional
    • 3.4. Market Trends
      • 3.4.1. Favorable supportive legislation by the government
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dementia Drugs, by Type, Application, Indication, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Dementia Drugs (Value)
      • 5.2.1. Global Dementia Drugs by: Type (Value)
        • 5.2.1.1. MAO Inhibitors
        • 5.2.1.2. Cholinesterase Inhibitors
        • 5.2.1.3. Glutamate Inhibitors
      • 5.2.2. Global Dementia Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Dementia Drugs by: Indication (Value)
        • 5.2.3.1. Lewy Body Dementia
        • 5.2.3.2. Parkinsons Disease Dementia
        • 5.2.3.3. Alzheimer's Disease
        • 5.2.3.4. Vascular Dementia
        • 5.2.3.5. Others
      • 5.2.4. Global Dementia Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
      • 5.2.5. Global Dementia Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Dementia Drugs (Volume)
      • 5.3.1. Global Dementia Drugs by: Type (Volume)
        • 5.3.1.1. MAO Inhibitors
        • 5.3.1.2. Cholinesterase Inhibitors
        • 5.3.1.3. Glutamate Inhibitors
      • 5.3.2. Global Dementia Drugs by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Dementia Drugs by: Indication (Volume)
        • 5.3.3.1. Lewy Body Dementia
        • 5.3.3.2. Parkinsons Disease Dementia
        • 5.3.3.3. Alzheimer's Disease
        • 5.3.3.4. Vascular Dementia
        • 5.3.3.5. Others
      • 5.3.4. Global Dementia Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Online
        • 5.3.4.2. Offline
      • 5.3.5. Global Dementia Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Dementia Drugs (Price)
      • 5.4.1. Global Dementia Drugs by: Type (Price)
  • 6. Dementia Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eisai, Inc (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biogen Pharmaceuticals(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Forest Laboratories, Inc(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca GmbH
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche(Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co., Inc(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Pfizer Inc(United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Dementia Drugs Sale, by Type, Application, Indication, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Dementia Drugs (Value)
      • 7.2.1. Global Dementia Drugs by: Type (Value)
        • 7.2.1.1. MAO Inhibitors
        • 7.2.1.2. Cholinesterase Inhibitors
        • 7.2.1.3. Glutamate Inhibitors
      • 7.2.2. Global Dementia Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Dementia Drugs by: Indication (Value)
        • 7.2.3.1. Lewy Body Dementia
        • 7.2.3.2. Parkinsons Disease Dementia
        • 7.2.3.3. Alzheimer's Disease
        • 7.2.3.4. Vascular Dementia
        • 7.2.3.5. Others
      • 7.2.4. Global Dementia Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
      • 7.2.5. Global Dementia Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Dementia Drugs (Volume)
      • 7.3.1. Global Dementia Drugs by: Type (Volume)
        • 7.3.1.1. MAO Inhibitors
        • 7.3.1.2. Cholinesterase Inhibitors
        • 7.3.1.3. Glutamate Inhibitors
      • 7.3.2. Global Dementia Drugs by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Dementia Drugs by: Indication (Volume)
        • 7.3.3.1. Lewy Body Dementia
        • 7.3.3.2. Parkinsons Disease Dementia
        • 7.3.3.3. Alzheimer's Disease
        • 7.3.3.4. Vascular Dementia
        • 7.3.3.5. Others
      • 7.3.4. Global Dementia Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Online
        • 7.3.4.2. Offline
      • 7.3.5. Global Dementia Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Dementia Drugs (Price)
      • 7.4.1. Global Dementia Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dementia Drugs: by Type(USD Million)
  • Table 2. Dementia Drugs MAO Inhibitors , by Region USD Million (2015-2020)
  • Table 3. Dementia Drugs Cholinesterase Inhibitors , by Region USD Million (2015-2020)
  • Table 4. Dementia Drugs Glutamate Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Dementia Drugs: by Application(USD Million)
  • Table 6. Dementia Drugs Hospital , by Region USD Million (2015-2020)
  • Table 7. Dementia Drugs Clinics , by Region USD Million (2015-2020)
  • Table 8. Dementia Drugs Others , by Region USD Million (2015-2020)
  • Table 9. Dementia Drugs: by Indication(USD Million)
  • Table 10. Dementia Drugs Lewy Body Dementia , by Region USD Million (2015-2020)
  • Table 11. Dementia Drugs Parkinsons Disease Dementia , by Region USD Million (2015-2020)
  • Table 12. Dementia Drugs Alzheimer's Disease , by Region USD Million (2015-2020)
  • Table 13. Dementia Drugs Vascular Dementia , by Region USD Million (2015-2020)
  • Table 14. Dementia Drugs Others , by Region USD Million (2015-2020)
  • Table 15. Dementia Drugs: by Distribution Channel(USD Million)
  • Table 16. Dementia Drugs Online , by Region USD Million (2015-2020)
  • Table 17. Dementia Drugs Offline , by Region USD Million (2015-2020)
  • Table 18. South America Dementia Drugs, by Country USD Million (2015-2020)
  • Table 19. South America Dementia Drugs, by Type USD Million (2015-2020)
  • Table 20. South America Dementia Drugs, by Application USD Million (2015-2020)
  • Table 21. South America Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 22. South America Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Dementia Drugs, by Type USD Million (2015-2020)
  • Table 24. Brazil Dementia Drugs, by Application USD Million (2015-2020)
  • Table 25. Brazil Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 26. Brazil Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 27. Argentina Dementia Drugs, by Type USD Million (2015-2020)
  • Table 28. Argentina Dementia Drugs, by Application USD Million (2015-2020)
  • Table 29. Argentina Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 30. Argentina Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Dementia Drugs, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Dementia Drugs, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 34. Rest of South America Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. Asia Pacific Dementia Drugs, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Dementia Drugs, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Dementia Drugs, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 39. Asia Pacific Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 40. China Dementia Drugs, by Type USD Million (2015-2020)
  • Table 41. China Dementia Drugs, by Application USD Million (2015-2020)
  • Table 42. China Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 43. China Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. Japan Dementia Drugs, by Type USD Million (2015-2020)
  • Table 45. Japan Dementia Drugs, by Application USD Million (2015-2020)
  • Table 46. Japan Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 47. Japan Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 48. India Dementia Drugs, by Type USD Million (2015-2020)
  • Table 49. India Dementia Drugs, by Application USD Million (2015-2020)
  • Table 50. India Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 51. India Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 52. South Korea Dementia Drugs, by Type USD Million (2015-2020)
  • Table 53. South Korea Dementia Drugs, by Application USD Million (2015-2020)
  • Table 54. South Korea Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 55. South Korea Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 56. Taiwan Dementia Drugs, by Type USD Million (2015-2020)
  • Table 57. Taiwan Dementia Drugs, by Application USD Million (2015-2020)
  • Table 58. Taiwan Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 59. Taiwan Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Australia Dementia Drugs, by Type USD Million (2015-2020)
  • Table 61. Australia Dementia Drugs, by Application USD Million (2015-2020)
  • Table 62. Australia Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 63. Australia Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Dementia Drugs, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Dementia Drugs, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 68. Europe Dementia Drugs, by Country USD Million (2015-2020)
  • Table 69. Europe Dementia Drugs, by Type USD Million (2015-2020)
  • Table 70. Europe Dementia Drugs, by Application USD Million (2015-2020)
  • Table 71. Europe Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 72. Europe Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 73. Germany Dementia Drugs, by Type USD Million (2015-2020)
  • Table 74. Germany Dementia Drugs, by Application USD Million (2015-2020)
  • Table 75. Germany Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 76. Germany Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 77. France Dementia Drugs, by Type USD Million (2015-2020)
  • Table 78. France Dementia Drugs, by Application USD Million (2015-2020)
  • Table 79. France Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 80. France Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 81. Italy Dementia Drugs, by Type USD Million (2015-2020)
  • Table 82. Italy Dementia Drugs, by Application USD Million (2015-2020)
  • Table 83. Italy Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 84. Italy Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 85. United Kingdom Dementia Drugs, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Dementia Drugs, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 88. United Kingdom Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. Netherlands Dementia Drugs, by Type USD Million (2015-2020)
  • Table 90. Netherlands Dementia Drugs, by Application USD Million (2015-2020)
  • Table 91. Netherlands Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 92. Netherlands Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 93. Rest of Europe Dementia Drugs, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Dementia Drugs, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 96. Rest of Europe Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 97. MEA Dementia Drugs, by Country USD Million (2015-2020)
  • Table 98. MEA Dementia Drugs, by Type USD Million (2015-2020)
  • Table 99. MEA Dementia Drugs, by Application USD Million (2015-2020)
  • Table 100. MEA Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 101. MEA Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 102. Middle East Dementia Drugs, by Type USD Million (2015-2020)
  • Table 103. Middle East Dementia Drugs, by Application USD Million (2015-2020)
  • Table 104. Middle East Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 105. Middle East Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 106. Africa Dementia Drugs, by Type USD Million (2015-2020)
  • Table 107. Africa Dementia Drugs, by Application USD Million (2015-2020)
  • Table 108. Africa Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 109. Africa Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 110. North America Dementia Drugs, by Country USD Million (2015-2020)
  • Table 111. North America Dementia Drugs, by Type USD Million (2015-2020)
  • Table 112. North America Dementia Drugs, by Application USD Million (2015-2020)
  • Table 113. North America Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 114. North America Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 115. United States Dementia Drugs, by Type USD Million (2015-2020)
  • Table 116. United States Dementia Drugs, by Application USD Million (2015-2020)
  • Table 117. United States Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 118. United States Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 119. Canada Dementia Drugs, by Type USD Million (2015-2020)
  • Table 120. Canada Dementia Drugs, by Application USD Million (2015-2020)
  • Table 121. Canada Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 122. Canada Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 123. Mexico Dementia Drugs, by Type USD Million (2015-2020)
  • Table 124. Mexico Dementia Drugs, by Application USD Million (2015-2020)
  • Table 125. Mexico Dementia Drugs, by Indication USD Million (2015-2020)
  • Table 126. Mexico Dementia Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 127. Dementia Drugs Sales: by Type(K Tons)
  • Table 128. Dementia Drugs Sales MAO Inhibitors , by Region K Tons (2015-2020)
  • Table 129. Dementia Drugs Sales Cholinesterase Inhibitors , by Region K Tons (2015-2020)
  • Table 130. Dementia Drugs Sales Glutamate Inhibitors , by Region K Tons (2015-2020)
  • Table 131. Dementia Drugs Sales: by Application(K Tons)
  • Table 132. Dementia Drugs Sales Hospital , by Region K Tons (2015-2020)
  • Table 133. Dementia Drugs Sales Clinics , by Region K Tons (2015-2020)
  • Table 134. Dementia Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 135. Dementia Drugs Sales: by Indication(K Tons)
  • Table 136. Dementia Drugs Sales Lewy Body Dementia , by Region K Tons (2015-2020)
  • Table 137. Dementia Drugs Sales Parkinsons Disease Dementia , by Region K Tons (2015-2020)
  • Table 138. Dementia Drugs Sales Alzheimer's Disease , by Region K Tons (2015-2020)
  • Table 139. Dementia Drugs Sales Vascular Dementia , by Region K Tons (2015-2020)
  • Table 140. Dementia Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 141. Dementia Drugs Sales: by Distribution Channel(K Tons)
  • Table 142. Dementia Drugs Sales Online , by Region K Tons (2015-2020)
  • Table 143. Dementia Drugs Sales Offline , by Region K Tons (2015-2020)
  • Table 144. South America Dementia Drugs Sales, by Country K Tons (2015-2020)
  • Table 145. South America Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 146. South America Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 147. South America Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 148. South America Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 149. Brazil Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 150. Brazil Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 151. Brazil Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 152. Brazil Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 153. Argentina Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 154. Argentina Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 155. Argentina Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 156. Argentina Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 157. Rest of South America Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 158. Rest of South America Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 159. Rest of South America Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 160. Rest of South America Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 161. Asia Pacific Dementia Drugs Sales, by Country K Tons (2015-2020)
  • Table 162. Asia Pacific Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 163. Asia Pacific Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 164. Asia Pacific Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 165. Asia Pacific Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. China Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 167. China Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 168. China Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 169. China Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. Japan Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 171. Japan Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 172. Japan Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 173. Japan Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. India Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 175. India Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 176. India Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 177. India Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 178. South Korea Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 179. South Korea Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 180. South Korea Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 181. South Korea Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 182. Taiwan Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 183. Taiwan Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 184. Taiwan Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 185. Taiwan Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 186. Australia Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 187. Australia Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 188. Australia Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 189. Australia Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 190. Rest of Asia-Pacific Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 191. Rest of Asia-Pacific Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 192. Rest of Asia-Pacific Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 193. Rest of Asia-Pacific Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 194. Europe Dementia Drugs Sales, by Country K Tons (2015-2020)
  • Table 195. Europe Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 196. Europe Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 197. Europe Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 198. Europe Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. Germany Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 200. Germany Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 201. Germany Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 202. Germany Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 203. France Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 204. France Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 205. France Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 206. France Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 207. Italy Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 208. Italy Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 209. Italy Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 210. Italy Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 211. United Kingdom Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 212. United Kingdom Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 213. United Kingdom Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 214. United Kingdom Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 215. Netherlands Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 216. Netherlands Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 217. Netherlands Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 218. Netherlands Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 219. Rest of Europe Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 220. Rest of Europe Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 221. Rest of Europe Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 222. Rest of Europe Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 223. MEA Dementia Drugs Sales, by Country K Tons (2015-2020)
  • Table 224. MEA Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 225. MEA Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 226. MEA Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 227. MEA Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. Middle East Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 229. Middle East Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 230. Middle East Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 231. Middle East Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 232. Africa Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 233. Africa Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 234. Africa Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 235. Africa Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 236. North America Dementia Drugs Sales, by Country K Tons (2015-2020)
  • Table 237. North America Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 238. North America Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 239. North America Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 240. North America Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 241. United States Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 242. United States Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 243. United States Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 244. United States Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 245. Canada Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 246. Canada Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 247. Canada Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 248. Canada Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 249. Mexico Dementia Drugs Sales, by Type K Tons (2015-2020)
  • Table 250. Mexico Dementia Drugs Sales, by Application K Tons (2015-2020)
  • Table 251. Mexico Dementia Drugs Sales, by Indication K Tons (2015-2020)
  • Table 252. Mexico Dementia Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 253. Dementia Drugs: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Dementia Drugs: by Type(USD Million)
  • Table 266. Dementia Drugs MAO Inhibitors , by Region USD Million (2021-2026)
  • Table 267. Dementia Drugs Cholinesterase Inhibitors , by Region USD Million (2021-2026)
  • Table 268. Dementia Drugs Glutamate Inhibitors , by Region USD Million (2021-2026)
  • Table 269. Dementia Drugs: by Application(USD Million)
  • Table 270. Dementia Drugs Hospital , by Region USD Million (2021-2026)
  • Table 271. Dementia Drugs Clinics , by Region USD Million (2021-2026)
  • Table 272. Dementia Drugs Others , by Region USD Million (2021-2026)
  • Table 273. Dementia Drugs: by Indication(USD Million)
  • Table 274. Dementia Drugs Lewy Body Dementia , by Region USD Million (2021-2026)
  • Table 275. Dementia Drugs Parkinsons Disease Dementia , by Region USD Million (2021-2026)
  • Table 276. Dementia Drugs Alzheimer's Disease , by Region USD Million (2021-2026)
  • Table 277. Dementia Drugs Vascular Dementia , by Region USD Million (2021-2026)
  • Table 278. Dementia Drugs Others , by Region USD Million (2021-2026)
  • Table 279. Dementia Drugs: by Distribution Channel(USD Million)
  • Table 280. Dementia Drugs Online , by Region USD Million (2021-2026)
  • Table 281. Dementia Drugs Offline , by Region USD Million (2021-2026)
  • Table 282. South America Dementia Drugs, by Country USD Million (2021-2026)
  • Table 283. South America Dementia Drugs, by Type USD Million (2021-2026)
  • Table 284. South America Dementia Drugs, by Application USD Million (2021-2026)
  • Table 285. South America Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 286. South America Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 287. Brazil Dementia Drugs, by Type USD Million (2021-2026)
  • Table 288. Brazil Dementia Drugs, by Application USD Million (2021-2026)
  • Table 289. Brazil Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 290. Brazil Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 291. Argentina Dementia Drugs, by Type USD Million (2021-2026)
  • Table 292. Argentina Dementia Drugs, by Application USD Million (2021-2026)
  • Table 293. Argentina Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 294. Argentina Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 295. Rest of South America Dementia Drugs, by Type USD Million (2021-2026)
  • Table 296. Rest of South America Dementia Drugs, by Application USD Million (2021-2026)
  • Table 297. Rest of South America Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 298. Rest of South America Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 299. Asia Pacific Dementia Drugs, by Country USD Million (2021-2026)
  • Table 300. Asia Pacific Dementia Drugs, by Type USD Million (2021-2026)
  • Table 301. Asia Pacific Dementia Drugs, by Application USD Million (2021-2026)
  • Table 302. Asia Pacific Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 303. Asia Pacific Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 304. China Dementia Drugs, by Type USD Million (2021-2026)
  • Table 305. China Dementia Drugs, by Application USD Million (2021-2026)
  • Table 306. China Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 307. China Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 308. Japan Dementia Drugs, by Type USD Million (2021-2026)
  • Table 309. Japan Dementia Drugs, by Application USD Million (2021-2026)
  • Table 310. Japan Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 311. Japan Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 312. India Dementia Drugs, by Type USD Million (2021-2026)
  • Table 313. India Dementia Drugs, by Application USD Million (2021-2026)
  • Table 314. India Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 315. India Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 316. South Korea Dementia Drugs, by Type USD Million (2021-2026)
  • Table 317. South Korea Dementia Drugs, by Application USD Million (2021-2026)
  • Table 318. South Korea Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 319. South Korea Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 320. Taiwan Dementia Drugs, by Type USD Million (2021-2026)
  • Table 321. Taiwan Dementia Drugs, by Application USD Million (2021-2026)
  • Table 322. Taiwan Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 323. Taiwan Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 324. Australia Dementia Drugs, by Type USD Million (2021-2026)
  • Table 325. Australia Dementia Drugs, by Application USD Million (2021-2026)
  • Table 326. Australia Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 327. Australia Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 328. Rest of Asia-Pacific Dementia Drugs, by Type USD Million (2021-2026)
  • Table 329. Rest of Asia-Pacific Dementia Drugs, by Application USD Million (2021-2026)
  • Table 330. Rest of Asia-Pacific Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 331. Rest of Asia-Pacific Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 332. Europe Dementia Drugs, by Country USD Million (2021-2026)
  • Table 333. Europe Dementia Drugs, by Type USD Million (2021-2026)
  • Table 334. Europe Dementia Drugs, by Application USD Million (2021-2026)
  • Table 335. Europe Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 336. Europe Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 337. Germany Dementia Drugs, by Type USD Million (2021-2026)
  • Table 338. Germany Dementia Drugs, by Application USD Million (2021-2026)
  • Table 339. Germany Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 340. Germany Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 341. France Dementia Drugs, by Type USD Million (2021-2026)
  • Table 342. France Dementia Drugs, by Application USD Million (2021-2026)
  • Table 343. France Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 344. France Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 345. Italy Dementia Drugs, by Type USD Million (2021-2026)
  • Table 346. Italy Dementia Drugs, by Application USD Million (2021-2026)
  • Table 347. Italy Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 348. Italy Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 349. United Kingdom Dementia Drugs, by Type USD Million (2021-2026)
  • Table 350. United Kingdom Dementia Drugs, by Application USD Million (2021-2026)
  • Table 351. United Kingdom Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 352. United Kingdom Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 353. Netherlands Dementia Drugs, by Type USD Million (2021-2026)
  • Table 354. Netherlands Dementia Drugs, by Application USD Million (2021-2026)
  • Table 355. Netherlands Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 356. Netherlands Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 357. Rest of Europe Dementia Drugs, by Type USD Million (2021-2026)
  • Table 358. Rest of Europe Dementia Drugs, by Application USD Million (2021-2026)
  • Table 359. Rest of Europe Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 360. Rest of Europe Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 361. MEA Dementia Drugs, by Country USD Million (2021-2026)
  • Table 362. MEA Dementia Drugs, by Type USD Million (2021-2026)
  • Table 363. MEA Dementia Drugs, by Application USD Million (2021-2026)
  • Table 364. MEA Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 365. MEA Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 366. Middle East Dementia Drugs, by Type USD Million (2021-2026)
  • Table 367. Middle East Dementia Drugs, by Application USD Million (2021-2026)
  • Table 368. Middle East Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 369. Middle East Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 370. Africa Dementia Drugs, by Type USD Million (2021-2026)
  • Table 371. Africa Dementia Drugs, by Application USD Million (2021-2026)
  • Table 372. Africa Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 373. Africa Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. North America Dementia Drugs, by Country USD Million (2021-2026)
  • Table 375. North America Dementia Drugs, by Type USD Million (2021-2026)
  • Table 376. North America Dementia Drugs, by Application USD Million (2021-2026)
  • Table 377. North America Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 378. North America Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 379. United States Dementia Drugs, by Type USD Million (2021-2026)
  • Table 380. United States Dementia Drugs, by Application USD Million (2021-2026)
  • Table 381. United States Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 382. United States Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 383. Canada Dementia Drugs, by Type USD Million (2021-2026)
  • Table 384. Canada Dementia Drugs, by Application USD Million (2021-2026)
  • Table 385. Canada Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 386. Canada Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 387. Mexico Dementia Drugs, by Type USD Million (2021-2026)
  • Table 388. Mexico Dementia Drugs, by Application USD Million (2021-2026)
  • Table 389. Mexico Dementia Drugs, by Indication USD Million (2021-2026)
  • Table 390. Mexico Dementia Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 391. Dementia Drugs Sales: by Type(K Tons)
  • Table 392. Dementia Drugs Sales MAO Inhibitors , by Region K Tons (2021-2026)
  • Table 393. Dementia Drugs Sales Cholinesterase Inhibitors , by Region K Tons (2021-2026)
  • Table 394. Dementia Drugs Sales Glutamate Inhibitors , by Region K Tons (2021-2026)
  • Table 395. Dementia Drugs Sales: by Application(K Tons)
  • Table 396. Dementia Drugs Sales Hospital , by Region K Tons (2021-2026)
  • Table 397. Dementia Drugs Sales Clinics , by Region K Tons (2021-2026)
  • Table 398. Dementia Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 399. Dementia Drugs Sales: by Indication(K Tons)
  • Table 400. Dementia Drugs Sales Lewy Body Dementia , by Region K Tons (2021-2026)
  • Table 401. Dementia Drugs Sales Parkinsons Disease Dementia , by Region K Tons (2021-2026)
  • Table 402. Dementia Drugs Sales Alzheimer's Disease , by Region K Tons (2021-2026)
  • Table 403. Dementia Drugs Sales Vascular Dementia , by Region K Tons (2021-2026)
  • Table 404. Dementia Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 405. Dementia Drugs Sales: by Distribution Channel(K Tons)
  • Table 406. Dementia Drugs Sales Online , by Region K Tons (2021-2026)
  • Table 407. Dementia Drugs Sales Offline , by Region K Tons (2021-2026)
  • Table 408. South America Dementia Drugs Sales, by Country K Tons (2021-2026)
  • Table 409. South America Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 410. South America Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 411. South America Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 412. South America Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 413. Brazil Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 414. Brazil Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 415. Brazil Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 416. Brazil Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 417. Argentina Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 418. Argentina Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 419. Argentina Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 420. Argentina Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 421. Rest of South America Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 422. Rest of South America Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 423. Rest of South America Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 424. Rest of South America Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 425. Asia Pacific Dementia Drugs Sales, by Country K Tons (2021-2026)
  • Table 426. Asia Pacific Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 427. Asia Pacific Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 428. Asia Pacific Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 429. Asia Pacific Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 430. China Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 431. China Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 432. China Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 433. China Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 434. Japan Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 435. Japan Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 436. Japan Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 437. Japan Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 438. India Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 439. India Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 440. India Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 441. India Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 442. South Korea Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 443. South Korea Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 444. South Korea Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 445. South Korea Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 446. Taiwan Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 447. Taiwan Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 448. Taiwan Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 449. Taiwan Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 450. Australia Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 451. Australia Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 452. Australia Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 453. Australia Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 454. Rest of Asia-Pacific Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 455. Rest of Asia-Pacific Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 456. Rest of Asia-Pacific Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 457. Rest of Asia-Pacific Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 458. Europe Dementia Drugs Sales, by Country K Tons (2021-2026)
  • Table 459. Europe Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 460. Europe Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 461. Europe Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 462. Europe Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 463. Germany Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 464. Germany Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 465. Germany Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 466. Germany Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 467. France Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 468. France Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 469. France Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 470. France Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 471. Italy Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 472. Italy Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 473. Italy Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 474. Italy Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 475. United Kingdom Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 476. United Kingdom Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 477. United Kingdom Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 478. United Kingdom Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 479. Netherlands Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 480. Netherlands Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 481. Netherlands Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 482. Netherlands Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 483. Rest of Europe Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 484. Rest of Europe Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 485. Rest of Europe Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 486. Rest of Europe Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 487. MEA Dementia Drugs Sales, by Country K Tons (2021-2026)
  • Table 488. MEA Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 489. MEA Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 490. MEA Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 491. MEA Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 492. Middle East Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 493. Middle East Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 494. Middle East Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 495. Middle East Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 496. Africa Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 497. Africa Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 498. Africa Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 499. Africa Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 500. North America Dementia Drugs Sales, by Country K Tons (2021-2026)
  • Table 501. North America Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 502. North America Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 503. North America Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 504. North America Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 505. United States Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 506. United States Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 507. United States Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 508. United States Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 509. Canada Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 510. Canada Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 511. Canada Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 512. Canada Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 513. Mexico Dementia Drugs Sales, by Type K Tons (2021-2026)
  • Table 514. Mexico Dementia Drugs Sales, by Application K Tons (2021-2026)
  • Table 515. Mexico Dementia Drugs Sales, by Indication K Tons (2021-2026)
  • Table 516. Mexico Dementia Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 517. Dementia Drugs: by Type(USD/Units)
  • Table 518. Research Programs/Design for This Report
  • Table 519. Key Data Information from Secondary Sources
  • Table 520. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dementia Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Dementia Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Dementia Drugs: by Indication USD Million (2015-2020)
  • Figure 7. Global Dementia Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Dementia Drugs Share (%), by Country
  • Figure 9. Asia Pacific Dementia Drugs Share (%), by Country
  • Figure 10. Europe Dementia Drugs Share (%), by Country
  • Figure 11. MEA Dementia Drugs Share (%), by Country
  • Figure 12. North America Dementia Drugs Share (%), by Country
  • Figure 13. Global Dementia Drugs: by Type K Tons (2015-2020)
  • Figure 14. Global Dementia Drugs: by Application K Tons (2015-2020)
  • Figure 15. Global Dementia Drugs: by Indication K Tons (2015-2020)
  • Figure 16. Global Dementia Drugs: by Distribution Channel K Tons (2015-2020)
  • Figure 17. South America Dementia Drugs Share (%), by Country
  • Figure 18. Asia Pacific Dementia Drugs Share (%), by Country
  • Figure 19. Europe Dementia Drugs Share (%), by Country
  • Figure 20. MEA Dementia Drugs Share (%), by Country
  • Figure 21. North America Dementia Drugs Share (%), by Country
  • Figure 22. Global Dementia Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Dementia Drugs share by Players 2020 (%)
  • Figure 24. Global Dementia Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Dementia Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Eisai, Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Eisai, Inc (Japan) Revenue: by Geography 2020
  • Figure 29. Janssen Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Janssen Pharmaceuticals, Inc (United States) Revenue: by Geography 2020
  • Figure 31. Biogen Pharmaceuticals(United States) Revenue, Net Income and Gross profit
  • Figure 32. Biogen Pharmaceuticals(United States) Revenue: by Geography 2020
  • Figure 33. Forest Laboratories, Inc(United States) Revenue, Net Income and Gross profit
  • Figure 34. Forest Laboratories, Inc(United States) Revenue: by Geography 2020
  • Figure 35. Eli Lilly and Company(United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company(United States) Revenue: by Geography 2020
  • Figure 37. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 39. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 40. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 41. AstraZeneca GmbH Revenue, Net Income and Gross profit
  • Figure 42. AstraZeneca GmbH Revenue: by Geography 2020
  • Figure 43. F. Hoffmann-La Roche(Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. F. Hoffmann-La Roche(Switzerland) Revenue: by Geography 2020
  • Figure 45. Merck & Co., Inc(United States) Revenue, Net Income and Gross profit
  • Figure 46. Merck & Co., Inc(United States) Revenue: by Geography 2020
  • Figure 47. Pfizer Inc(United States) Revenue, Net Income and Gross profit
  • Figure 48. Pfizer Inc(United States) Revenue: by Geography 2020
  • Figure 49. Global Dementia Drugs: by Type USD Million (2021-2026)
  • Figure 50. Global Dementia Drugs: by Application USD Million (2021-2026)
  • Figure 51. Global Dementia Drugs: by Indication USD Million (2021-2026)
  • Figure 52. Global Dementia Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 53. South America Dementia Drugs Share (%), by Country
  • Figure 54. Asia Pacific Dementia Drugs Share (%), by Country
  • Figure 55. Europe Dementia Drugs Share (%), by Country
  • Figure 56. MEA Dementia Drugs Share (%), by Country
  • Figure 57. North America Dementia Drugs Share (%), by Country
  • Figure 58. Global Dementia Drugs: by Type K Tons (2021-2026)
  • Figure 59. Global Dementia Drugs: by Application K Tons (2021-2026)
  • Figure 60. Global Dementia Drugs: by Indication K Tons (2021-2026)
  • Figure 61. Global Dementia Drugs: by Distribution Channel K Tons (2021-2026)
  • Figure 62. South America Dementia Drugs Share (%), by Country
  • Figure 63. Asia Pacific Dementia Drugs Share (%), by Country
  • Figure 64. Europe Dementia Drugs Share (%), by Country
  • Figure 65. MEA Dementia Drugs Share (%), by Country
  • Figure 66. North America Dementia Drugs Share (%), by Country
  • Figure 67. Global Dementia Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Eisai, Inc (Japan)
  • Janssen Pharmaceuticals, Inc (United States)
  • Biogen Pharmaceuticals(United States)
  • Forest Laboratories, Inc(United States)
  • Eli Lilly and Company(United States)
  • Novartis AG (Switzerland)
  • Sanofi S.A (France)
  • AstraZeneca GmbH
  • F. Hoffmann-La Roche(Switzerland)
  • Merck & Co., Inc(United States)
  • Pfizer Inc(United States)
Additional players considered in the study are as follows:
Valeant Pharmaceutical International(United States) , Teva Pharmaceuticals Industries(United States)
Select User Access Type

Key Highlights of Report


Nov 2021 248 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dementia Drugs Quantitative research analysis
Global Dementia Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"The growing geriatric population" is seen as one of major growth factors of Dementia Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Dementia Drugs Market in coming years.

Know More About Global Dementia Drugs Report?

Have a Query? Click Here

Other Related Reports

Liposome Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel), Application (Pharmaceutical, Cosmetic, Food, Farming), Therapy (Fungal Infe...
$ 3350
Anti-infective Agents Comprehensive Study by Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Application (Hospital Use, Clinic Use, Household, Other), Drug Type (Penicillins, Sulfonami...
$ 3750
Legal Marijuana Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players ...
$ 3500
Veterinary Drugs Comprehensive Study by Type (Antibiotics, Non-Steroidal Anti-Inflammatories, Steroids, Opioid Pain Relievers, Anti-Parasitics, Behavior-Modifying Drugs and Sedatives, Hormones, Chemo...
$ 3750
Divalproex Sodium Comprehensive Study by Type (Tablet, Capsule, Others), Application (Epilepsy, Manic-Depressive Illness, Migraine Prophylaxis, Other), Sales Channel (Hospital Pharmacies, Online Phar...
$ 3450
Albumin Comprehensive Study by Type (Human Serum Albumin, Recombinant Albumin), Application (Drug Formulation, Vaccines, Medical Device Coating, Culture Medium & Stabilizer, Diagnostics, In Vitro Fer...
$ 3450